![Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer | Business Wire Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20220604005002/en/1045874/23/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer | Business Wire
![PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jgo/2017/jgo.2017.3.issue-4/jgo.2016.008318/20170922/images/large/jgo.2016.008318t3.jpeg)
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine
![Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ... Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ...](https://www.annalsofoncology.org/cms/asset/a6bf541c-0c4d-4eee-9a7c-317d0eb4a315/gr1.jpg)
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ...
![Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1652958293301774436628624553b22c.png)
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
![PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jgo/2017/jgo.2017.3.issue-4/jgo.2016.008318/20170922/images/large/jgo.2016.008318t1.jpeg)
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine
![Sara Tolaney on Twitter: "PALOMA-3 updated OS data: improved in pts without prior chemotherapy @OncoAlert #bcsm #ASCO21 https://t.co/qGlOgPb6IZ" / Twitter Sara Tolaney on Twitter: "PALOMA-3 updated OS data: improved in pts without prior chemotherapy @OncoAlert #bcsm #ASCO21 https://t.co/qGlOgPb6IZ" / Twitter](https://pbs.twimg.com/media/E3It-ftWUAYTvru.jpg)
Sara Tolaney on Twitter: "PALOMA-3 updated OS data: improved in pts without prior chemotherapy @OncoAlert #bcsm #ASCO21 https://t.co/qGlOgPb6IZ" / Twitter
![PDF) Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials PDF) Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials](https://www.researchgate.net/publication/343610464/figure/fig3/AS:937396321415170@1600504107224/PALOMA-3-STEPP-analyses-evaluating-OS-effect-in-patients-who-received-adjuvant-therapy-a_Q320.jpg)
PDF) Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
![PALOMA-3 biomarker analysis: Liquid biopsy could ID progression risk | MDedge Hematology and Oncology PALOMA-3 biomarker analysis: Liquid biopsy could ID progression risk | MDedge Hematology and Oncology](https://cdn.mdedge.com/files/s3fs-public/140974_OLeary_Ben_web.jpg)
PALOMA-3 biomarker analysis: Liquid biopsy could ID progression risk | MDedge Hematology and Oncology
![Dr. Iván R. González on Twitter: "#Day2 #ASCO21 #BreastCancer—Metastatic #PALOMA3 @ASCO @ASCO_pubs @OncoAlert @AndreaAnampaG @IshwariaMD @neerajaiims @tmprowell @crisbergerot @DrChoueiri @GlopesMd @VivekSubbiah @ASCO_pubs @weoncologists https://t.co ... Dr. Iván R. González on Twitter: "#Day2 #ASCO21 #BreastCancer—Metastatic #PALOMA3 @ASCO @ASCO_pubs @OncoAlert @AndreaAnampaG @IshwariaMD @neerajaiims @tmprowell @crisbergerot @DrChoueiri @GlopesMd @VivekSubbiah @ASCO_pubs @weoncologists https://t.co ...](https://pbs.twimg.com/media/E3IsmzNXwAATdql.jpg)
Dr. Iván R. González on Twitter: "#Day2 #ASCO21 #BreastCancer—Metastatic #PALOMA3 @ASCO @ASCO_pubs @OncoAlert @AndreaAnampaG @IshwariaMD @neerajaiims @tmprowell @crisbergerot @DrChoueiri @GlopesMd @VivekSubbiah @ASCO_pubs @weoncologists https://t.co ...
![Metastatic Breast Cancer: Experts Discuss the Impact of Therapeutic Complexity on Practice Patterns in America This activity is supported by educational. - ppt download Metastatic Breast Cancer: Experts Discuss the Impact of Therapeutic Complexity on Practice Patterns in America This activity is supported by educational. - ppt download](https://images.slideplayer.com/42/11465265/slides/slide_22.jpg)
Metastatic Breast Cancer: Experts Discuss the Impact of Therapeutic Complexity on Practice Patterns in America This activity is supported by educational. - ppt download
![Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ... Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ...](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420432211-gr3.jpg)
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ...
![Current endocrine therapy in case of post-menopausal metastatic luminal... | Download Scientific Diagram Current endocrine therapy in case of post-menopausal metastatic luminal... | Download Scientific Diagram](https://www.researchgate.net/publication/332765656/figure/fig1/AS:753442834362370@1556646178832/Current-endocrine-therapy-in-case-of-post-menopausal-metastatic-luminal-breast-cancer.png)
Current endocrine therapy in case of post-menopausal metastatic luminal... | Download Scientific Diagram
![Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1654693914114966111062a0a01a2a48a.jpg)
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
![ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate](https://d2ogjlfjkptkow.cloudfront.net/contentimage/30849.jpg)
ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate
![PDF) Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials PDF) Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials](https://www.researchgate.net/publication/343610464/figure/fig4/AS:937396321411074@1600504107250/PALOMA-3-PFS-by-Subtype-Distribution-a-Intrinsic-subtype-distribution-of-tumors-and-PFS_Q320.jpg)
PDF) Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
![PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jgo/2017/jgo.2017.3.issue-4/jgo.2016.008318/20170922/images/large/jgo.2016.008318t2.jpeg)